Related Experiment Video

Updated: Jul 9, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Hepatic steatosis and fibrosis in chronic hepatitis C in Taiwan

Meng-Hsuan Hsieh1, Li-Po Lee, Ming-Yen Hsieh

  • 1Department of Occupational and Environmental Medicine, Kaohsiung Municipal HsiaoKang Hospital, Kaohsiung, Taiwan.

Japanese Journal of Infectious Diseases
|November 23, 2007
PubMed

Insights

Hepatic steatosis, or fatty liver, is common in Hepatitis C virus (HCV) infection. It is linked to liver fibrosis and triglyceride levels, not viral load.

Area of Science:

  • Hepatology
  • Virology
  • Gastroenterology

Background:

  • Hepatitis C virus (HCV) infection is known to associate with hepatic steatosis (fatty liver).
  • The precise role of hepatic steatosis in the pathogenesis of HCV infection requires further elucidation.
  • Understanding these associations is crucial for managing chronic hepatitis C.

Purpose of the Study:

  • To investigate the prevalence and clinical significance of hepatic steatosis in patients with chronic hepatitis C.
  • To identify risk factors associated with hepatic steatosis in this patient cohort.
  • To determine the relationship between hepatic steatosis and disease severity markers.

Main Methods:

  • A cohort of 425 patients with biopsy-proven chronic hepatitis C were analyzed.
  • Hepatic steatosis was scored using established histopathological methods (Kleiner, Knodell, Scheuer).
  • HCV RNA levels, genotypes, body mass index (BMI), and triglyceride levels were assessed.

Main Results:

  • Hepatic steatosis was present in 30.8% of patients, with mild, moderate, and severe forms observed.
  • Lower BMI (<23 kg/m²) was significantly associated with a reduced rate of hepatic steatosis (18.9%).
  • Hepatic steatosis correlated with hepatic fibrosis (P=0.035) but not with necroinflammatory activity or HCV RNA levels.
  • Multivariate analysis identified BMI, hepatic fibrosis, and triglyceride levels as significant risk factors for hepatic steatosis.

Conclusions:

  • Hepatic steatosis is a common finding in chronic hepatitis C patients.
  • Body mass index is the strongest predictor of hepatic steatosis, followed by hepatic fibrosis and triglyceride levels.
  • Hepatic steatosis is associated with overweight, hepatic fibrosis, and elevated triglycerides in chronic hepatitis C.

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...